IL-36RN Antibody
| Code | Size | Price |
|---|
| PSI-7511-0.02mg | 0.02mg | £150.00 |
Quantity:
| PSI-7511-0.1mg | 0.1mg | £449.00 |
Quantity:
Prices exclude any Taxes / VAT
Overview
Host Type: Rabbit
Antibody Isotype: IgG
Antibody Clonality: Polyclonal
Regulatory Status: RUO
Applications:
- Enzyme-Linked Immunosorbent Assay (ELISA)
- Immunofluorescence (IF)
- Immunohistochemistry (IHC)
- Western Blot (WB)
Documents
Further Information
Additional Names:
IL-36RN Antibody: FIL1, FIL1D, IL1F5, IL1L1, PSORP, IL1HY1, IL1RP3, IL36RA, FIL1(DELTA), UNQ1896/PRO4342, Interleukin-36 receptor antagonist protein, FIL1 delta, IL-1RP3
Application Note:
IL-36RN antibody can be used for detection of IL-36RN by Western blot at 1 μg/ml.
Antibody validated: Western Blot in human samples; Immunohistochemistry in rat samples and Immunofluorescence in rat samples. All other applications and species not yet tested.
Antibody validated: Western Blot in human samples; Immunohistochemistry in rat samples and Immunofluorescence in rat samples. All other applications and species not yet tested.
Background:
IL-36RN is is a member of the interleukin 1 cytokine family whose gene and eight other interleukin 1 family genes form a cytokine gene cluster on chromosome 2 (1). IL-36RN specifically inhibits the activation of NF-kappaB induced IL-36A (2). The opposing activities of these cytokines have been suggested to be involved in the regulation of skin inflammation (3). Like the IL-36 cytokines (IL-36A, IL-36B and IL-36G), IL-36RN requires post-translational processing for full agonist activity, but the cleavage mechanism is currently unknown (4).
Background References:
- Smith DE, Renshaw BR, Ketchem RR, et al. Four new members expand the interleukin-1 superfamily. J. Biol. Chem. 2000; 275:1169-75.
- Debets R, Timans JC, Homey B, et al. Two novel IL-1 family members, IL-1 delta and IL-1 epsilon, function as an antagonist and agonist of NF-kappa B activation through the orphan IL-1 receptor-related protein 2. J. Immunol. 2001; 167:1440-6.
- Blumberg H, Dinh H, Trueblood ES, et al. Opposing activities of two novel members of the IL-1 ligand family regulate skin inflammation. J. Exp. Med. 2007; 204:2603-14.
- Towne JE, Renshaw BR, Douangpanya J, et al. Interleukin-36 (IL-36) ligands require processing for full agonist agonist (IL-36a, IL-36b, and IL-36g) or antagonist (IL-36Ra) activity. J. Biol. Chem. 2011; 286:42594-602.
Buffer:
IL-36RN antibody is supplied in PBS containing 0.02% sodium azide.
Concentration:
1 mg/mL
Conjugate:
Unconjugated
DISCLAIMER:
Optimal dilutions/concentrations should be determined by the end user. The information provided is a guideline for product use. This product is for research use only.
Immunogen:
IL-36RN antibody was raised against a 19 amino acid peptide near the carboxy terminus of human IL-36RN.
The immunogen is located within the last 50 amino acids of IL-36RN.
The immunogen is located within the last 50 amino acids of IL-36RN.
NCBI Gene ID #:
26525
NCBI Official Name:
interleukin 36 receptor antagonist
NCBI Official Symbol:
IL36RN
NCBI Organism:
homo sapiens
Physical State:
Liquid
PREDICTED MOLECULAR WEIGHT:
Observed Molecular Weight: 24 kDa
Protein Accession #:
NP_775262
Protein GI Number:
27894310
Purification:
IL-36RN antibody is affinity chromatography purified via peptide column.
Research Area:
Immunology
SPECIFICITY:
IL-36RN antibody is human and mouse reactive. At least two isoforms of IL-36RN are known to exist
Swissprot #:
Q9UBH0
User NOte:
Optimal dilutions for each application to be determined by the researcher.
Related Products
| Product Name | Product Code | Supplier | IL-36RN Peptide | PSI-7511P | ProSci | Summary Details | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|